Fineline Cube

Follow:
14484 Articles
Keymed Biosciences Presents CM336 Data for Relapsed Multiple Myeloma at ASH Annual Meeting
CompanyDrug

Keymed Biosciences Presents CM336 Data for Relapsed Multiple Myeloma at ASH Annual Meeting

Antengene's Xpovio Showcases Positive Results in Phase III BENCH and Phase I/II TOUCH Studies at ASH 2024
CompanyDrug

Antengene’s Xpovio Showcases Positive Results in Phase III BENCH and Phase I/II TOUCH Studies at ASH 2024

Lee's Pharmaceutical Receives NMPA Approval for Generic Glaucoma Treatments
CompanyDrug

Lee’s Pharmaceutical Receives NMPA Approval for Generic Glaucoma Treatments

NMPA Proposes Draft for Simplified Registration of Traditional Chinese Medicines from Hong Kong and Macao
Policy / Regulatory

NMPA Proposes Draft for Simplified Registration of Traditional Chinese Medicines from Hong Kong and Macao

China's NHSA and NHC Issue Guidelines to Enhance Volume-based Procurement Mechanism
Policy / Regulatory

China’s NHSA and NHC Issue Guidelines to Enhance Volume-based Procurement Mechanism

CSPC Pharmaceutical Group's SYHX2011 for Metastatic Breast Cancer Accepted for NMPA Review
CompanyDrug

CSPC Pharmaceutical Group’s SYHX2011 for Metastatic Breast Cancer Accepted for NMPA Review

GSK's Nucala Receives FDA Review for COPD Indication Based on MATINEE Study Data
CompanyDrug

GSK’s Nucala Receives FDA Review for COPD Indication Based on MATINEE Study Data

Hantech Medical Device Co., Ltd Acquires BD's Villamarzana Factory to Expand Manufacturing
CompanyDeals

Hantech Medical Device Co., Ltd Acquires BD’s Villamarzana Factory to Expand Manufacturing

Precision Biotech and T&L Biotechnology Form Partnership to Advance Cell and Gene Therapies
CompanyDeals

Precision Biotech and T&L Biotechnology Form Partnership to Advance Cell and Gene Therapies

MicroPort Scientific Corp. Launches FireFalcon Balloon for Coronary Interventions with NMPA Approval
CompanyMedical Device

MicroPort Scientific Corp. Launches FireFalcon Balloon for Coronary Interventions with NMPA Approval

HuidaGene Therapeutics Initiates HERO Trial for RNA-Editing Therapy HG204 in MECP2 Duplication Syndrome
CompanyDrug

HuidaGene Therapeutics Initiates HERO Trial for RNA-Editing Therapy HG204 in MECP2 Duplication Syndrome

Simcere Pharmaceutical's SIM0508 Reaches First Patient Dosing in Global Clinical Study
CompanyDrug

Simcere Pharmaceutical’s SIM0508 Reaches First Patient Dosing in Global Clinical Study